Lieberman J A, Johns C A, Kane J M, Rai K, Pisciotta A V, Saltz B L, Howard A
Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, NY 11004.
J Clin Psychiatry. 1988 Jul;49(7):271-7.
Clozapine, an atypical neuroleptic with unique clinical and preclinical properties, represents a potentially valuable addition to the psychopharmacopeia. Its development and use have been limited by its higher frequency, compared with other pharmacologic treatments, of the potentially fatal side effect of agranulocytosis. This article describes the natural history of five cases of agranulocytosis that occurred in the course of clozapine treatment. The cases were generally uniform as to onset, recovery, and hematologic features. No patient had hematologic reactions to treatment with psychotropic agents before or after clozapine treatment. These findings, along with other work in progress, suggest that clozapine's granulocytoxic effects are produced by a highly specific immune-mediated mechanism.
氯氮平是一种具有独特临床和临床前特性的非典型抗精神病药物,是精神药物学中一种潜在的有价值的补充药物。与其他药物治疗相比,其粒细胞缺乏症这一潜在致命副作用的发生率较高,限制了它的开发和使用。本文描述了在氯氮平治疗过程中发生的5例粒细胞缺乏症的自然病程。这些病例在发病、恢复和血液学特征方面基本一致。在氯氮平治疗之前或之后,没有患者对精神药物治疗产生血液学反应。这些发现以及其他正在进行的研究表明,氯氮平的粒细胞毒性作用是由一种高度特异性的免疫介导机制产生的。